Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715341 | 0.88 | ALDH1A1 (0.41) | AGTR1L3MBTL1TDP1ALDH1A1LMNA | |
| SCHEMBL4716103 | 0.86 | MEN1 (0.51) | AGTR1L3MBTL1GAAALDH1A1LMNA | |
| SCHEMBL4716188 | 0.85 | AGTR1 (0.53) | AGTR1L3MBTL1CASP6ALDH1A1 | |
| SCHEMBL4716022 | 0.84 | ALDH1A1 (0.55) | USP2AGTR1L3MBTL1GAAALDH1A1 | |
| SCHEMBL5746636 | 0.82 | MAPT (0.40) | AGTR1L3MBTL1TDP1ALDH1A1HTT | |
| SCHEMBL4713080 | 0.81 | TSHR (0.52) | USP2TDP1APAF1UBE2NALDH1A1 | |
| SCHEMBL4716298 | 0.81 | MCOLN3 (0.54) | AGTR1L3MBTL1CASP6GAAALDH1A1 | |
| SCHEMBL4715768 | 0.80 | MAPT (0.56) | USP2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4716303 | 0.79 | MEN1 (0.51) | USP2AGTR1GAAALDH1A1LMNA | |
| SCHEMBL4713545 | 0.77 | TSHR (0.57) | L3MBTL1CASP6GAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | USP2 2811/4885AGTR1 612/4885L3MBTL1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.